Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.42 |
| ▸ | KIF11 | P52732 | 4/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310038 | 0.85 | MAPT (0.41) | ERN1KIF11CA9ALDH1A1MAPT | |
| SCHEMBL5737107 | 0.84 | KIF11 (0.47) | ERN1KIF11 | |
| SCHEMBL2535056 | 0.79 | ERN1 (0.60) | ERN1MAPT | |
| SCHEMBL1125758 | 0.78 | ERN1 (0.50) | ERN1ALDH1A1MAPT | |
| SCHEMBL17806545 | 0.77 | KIF11 (0.48) | KIF11AKR1C3AKR1C2CA12CA9 | |
| SCHEMBL4600136 | 0.77 | ERN1 (0.51) | ERN1ALDH1A1MAPT | |
| SCHEMBL1125185 | 0.77 | ERN1 (0.53) | ERN1KIF11 | |
| SCHEMBL20861958 | 0.77 | ERN1 (0.37) | ERN1KIF11 | |
| SCHEMBL14524923 | 0.76 | ERN1 (0.40) | ERN1KIF11CA12CA9 | |
| SCHEMBL5734212 | 0.75 | PTGS2 (0.41) | ERN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244446-B1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| US-6858630-B2 | Naphthimidazole derivatives and their use as thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | SMITHKLINE BEECHAM CORPORATION | 2003-05-01 | — | — | US | disclosed |
| EP-1244446-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1244446-A1 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001039773-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | MPL, THPO, TPO | ERN1 2498/4885KIF11 2203/4885AKR1C3 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.